DOCSLIB.ORG

Cellular Immunology Ubiquitination and Phosphorylation of The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Cellular Immunology 340 (2019) 103877 Contents lists available at ScienceDirect Cellular Immunology journal homepage: www.elsevier.com/locate/ycimm Review article Ubiquitination and phosphorylation of the CARD11-BCL10-MALT1 T signalosome in T cells ⁎ Marie Lorka,b, Jens Staala,b, Rudi Beyaerta,b, a Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium b Unit of Molecular Signal Transduction in Inflammation, Center for Inflammation Research, VIB, Ghent, Belgium ARTICLE INFO ABSTRACT Keywords: Antigen receptor-induced signaling plays an important role in inflammation and immunity. Formation ofa T cells CARD11-BCL10-MALT1 (CBM) signaling complex is a key event in T- and B cell receptor-induced gene ex- Lymphocytes pression by regulating NF-κB activation and mRNA stability. Deregulated CARD11, BCL10 or MALT1 expression CARD11 or CBM signaling have been associated with immunodeficiency, autoimmunity and cancer, indicating that CBM MALT1 formation and function have to be tightly regulated. Over the past years great progress has been made in de- BCL10 ciphering the molecular mechanisms of assembly and disassembly of the CBM complex. In this context, several Ubiquitin Phosphorylation posttranslational modifications play an indispensable role in regulating CBM function and downstream signal Inflammation transduction. In this review we summarize how the different CBM components as well as their interplay are Immunity regulated by protein ubiquitination and phosphorylation in the context of T cell receptor signaling. NF-κB Abbreviations: ABC-DLBCL, activated-B-Cell-like diffuse large B cell lymphoma; ADAP, adhesion and degranulation-promoting adapter protein; AIP, AHreceptor- interacting protein; Akt, protein kinase B; AP-1, activator protein 1; API2, apoptosis Inhibitor 2; ATG12, autophagy related 12; BCL10, B-cell lymphoma/leukemia 10; BCR, B cell receptor; BENTA, B cell expansion with NF-κB and T cell anergy; βTRCP, β-transducing repeat-containing protein; BIR, baculoviral inhibitor of apoptosis (IAP)-repeats; BIRC3, baculoviral inhibitor of apoptosis (IAP) repeat-containing 3; CaMK, Ca2+/calmodulin-dependent kinase; CARD, caspase recruitment domain; CARD11, caspase recruitment domain family member 11; Carma, caspase recruitment domain (CARD)-containing MAGUK proteins; Cbl-b, casitas B-lineage lym- phoma proto-oncogene-b; CBM, CARD11-BCL10-MALT1 complex; cIAP, cellular inhibitor of apoptosis; CID, combined immunodeficiency; CK1α, casein kinase 1α; CYLD, cylindromatosis; DAG, diacylglycerol; DUB, deubiquitinase; Erk1, extracellular signal-regulated kinase 1; FOXP3, forkhead box P3; GSK3β, glycogen synthase kinase 3 beta; GST, glutathione S-transferase; GUK, guanylate kinase-like; HECT, homologous to the E6AP carboxyl terminus; HOIL-1, heme-oxidized IRP2 ligase-1; HOIP, heme-oxidized IRP2 ligase-1 (HOIL-1)-Interacting Protein; HPK1, hematopoietic progenitor kinase 1; Ig, immunoglobulin; IKK, IκB kinase; IP3, inositol trisphosphate; ITAM, immunoreceptor tyrosine-based activation motif; ITCH, itchy E3 ubiquitin protein ligase; IκBα, inhibitor of NF-κB α; JNK, c-jun N-terminal kinase; LAMP1, lysosomal-associated membrane protein 1; LAT, linker for the activation of T cells; LC3, microtubule-associated protein 1A/1B-light chain 3; Lck, lymphocyte cell-specific protein-tyrosine kinase; LUBAC, linear ubiquitin chain assembly complex; MAGUK, membrane-associated guanylate kinase; MALT1,mu- cosa-associated lymphoid tissue lymphoma translocation protein 1; MAPK, mitogen-associated protein kinase; MHC, major histocompatibility complex; MIB2, mindbomb E3 ubiquitin protein ligase 2; NEDD, neuronal precursor cell-expressed developmentally downregulated; NEMO, NF-κB essential modulator; NF-AT, nuclear factor of activated T cells; NF-κB, nuclear factor-κB; NKT, natural killer T cell; NZF, Npl4 zinc finger domain; p62, sequestosome 1; PDZ, postsynaptic density 95/disc large/zona occludens 1 domain; PI3K, phosphoinositide 3-kinase; PIP2, phosphatidylinositol 4,5 bisphosphate; PKC, protein kinase C; PLCγ, phospholipase C; PMA, phorbol 12-myristate 13-acetate; POLKADOTS, punctate and oligomeric killing or activating domains transducing signals; PP2A, protein phosphatase 2; PRD, PKC regulated domain; PTM, posttranslational modification; RIPK2, receptor interacting serine/threonine kinase 2; RNF, ring finger protein; SH3, Src homology3; SHARPIN, SHANK associated RH domain interactor; SLP-76, Src homology 2 domain-containing leukocyte phosphoprotein of 76 kDa; STUB1, Stress Induced Phosphoprotein 1 (STIP1) homology and U-box containing protein 1; SUMO, Small ubiquitin-like modifier; TAB2/3, TAK1-binding proteins 2 and 3; TAK1, Transforming growth factor beta (TGFβ)-activated kinase 1; TBK1, TRAF Family Member Associated NF-κB Activator (TANK) binding kinase 1; TCR, T cell receptor; TRAF6, tumor necrosis factor (TNF) receptor-associated factor 6; T6BM, TRAF6-binding motif; UBAN, ubiquitin binding in A20 binding inhibitor of NF-κB (ABIN) and NEMO; Ubc13, ubiquitin conjugating enzyme E2N; UBD, ubiquitin binding domain; Uev1A, ubiquitin-conjugating enzyme E2 variant 1; USP, ubiquitin-specific protease; ZAP-70, ζ-associated protein of 70 kDa ⁎ Corresponding author at: Center for Inflammation Research, VIB-Ghent University, Technologiepark 927, B-9052 Ghent, Belgium. E-mail address: [email protected] (R. Beyaert). https://doi.org/10.1016/j.cellimm.2018.11.001 Received 21 August 2018; Accepted 2 November 2018 Available online 01 December 2018 0008-8749/ © 2018 Elsevier Inc. All rights reserved. M. Lork, et al. Cellular Immunology 340 (2019) 103877 1. Introduction the covalent attachment of ubiquitin to the side chain of a lysine (K) residue in a target protein requires the concerted action of three dif- The immune system is a complex interplay between different cells, ferent enzymes: an ubiquitin-activating enzyme (E1), an ubiquitin tissues and organs, developed to protect the organism from invading conjugating enzyme (E2), and an ubiquitin ligase enzyme (E3) (Fig. 1). threats. As a signaling system, the immune system is facing a unique Ubiquitin itself contains seven lysine residues that can also serve as and interesting challenge in that pathogens typically have much shorter ubiquitin acceptor sites, allowing the formation of structurally different generation times and consequently evolve much faster than their hosts, types of polyubiquitin chains (K6, K11, K27, K29, K33, K48 and K63). which means that the immune system needs to be vigilant and re- In addition, a ubiquitin molecule can be attached to the N-terminal sponsive to novel threats. At the same time is a poorly regulated im- methionine (M1) of the proximal ubiquitin residue, leading to the for- mune response detrimental to the organism, which means that an ef- mation of linear ubiquitin or M1 chains [4]. Different types of poly- fective negative regulation of immune responses is also important. ubiquitination form a kind of ubiquitin code that is recognized by Physical barriers and the innate immune system serve as the first lines specific ubiquitin-binding domain (UBD)-containing proteins that of defense. Conserved components of pathogens are sensed by pattern mediate downstream signaling. Ubiquitin can also be attached to serine, recognition receptors on cells, which elicit an innate immune response threonine or cysteine residues, but they are less stable and to date very by production of antimicrobial factors and inflammatory mediators. little is known about these modifications [5]. The ubiquitin code proved Innate immunity also regulates the recruitment and activation of to be even more complex when mixed chain types such as M1/K63 and adaptive immune cells [1]. Adaptive immunity depends on T and B K48/K63 hybrid chains were identified [6,7]. There are also hybrid lymphocytes carrying highly specific antigen-recognition receptors, the chains of ubiquitin-like modifications and ubiquitin such as ubiquitin- B cell receptor (BCR) and T cell receptor (TCR). Once activated, B cells SUMO or ubiquitin-NEDD8 hybrid conjugates. Furthermore, ubiquitin produce antibodies against pathogens mediating the humoral immune itself can be subject to PTMs, for example acetylation of its lysine re- response. CD4 T cells help B cells in the humoral response, while CD8 T sidues or phosphorylation on serine (S), threonine (T) or tyrosine (Y) cells and natural killer cells play a role in the cell-mediated immune residues. In particular S65 phosphorylation has been studied ex- response to e.g. kill virus infected cells or cancer cells [2]. tensively in the context of mitophagy [8]. Each of these ubiquitin Immune cell signal transduction needs to be tightly regulated, modifications can alter the charge and surface properties of ubiquitin which highly depends on posttranslational modifications (PTMs). There and can hence dramatically affect signaling outcome. While K48-linked is a wide range of PTMs like acetylation, lipid conjugations, oxidation, polyubiquitination mainly targets proteins for proteasomal degrada- phosphorylation, proteolytic processing, ubiquitination and ubiquitin- tion, K63- and M1-linked polyubiquitin chains can regulate protein like modification, which all can play a direct role in signal transduction, activity, protein subcellular localization or protein-protein interaction but possibly also serve as “memory” to influence or cross-talk with in various signaling pathways [9]. Like phosphorylation, ubiquitination other signaling events. This complex change in the
Recommended publications
  • The Role of the Ubiquitin Ligase Nedd4-1 in Skeletal Muscle Atrophy

    The Role of the Ubiquitin Ligase Nedd4-1 in Skeletal Muscle Atrophy

    The Role of the Ubiquitin Ligase Nedd4-1 in Skeletal Muscle Atrophy by Preena Nagpal A thesis submitted in conformity with the requirements for the degree of Masters in Medical Science Institute of Medical Science University of Toronto © Copyright by Preena Nagpal 2012 The Role of the Ubiquitin Ligase Nedd4-1 in Skeletal Muscle Atrophy Preena Nagpal Masters in Medical Science Institute of Medical Science University of Toronto 2012 Abstract Skeletal muscle (SM) atrophy complicates many illnesses, diminishing quality of life and increasing disease morbidity, health resource utilization and health care costs. In animal models of muscle atrophy, loss of SM mass results predominantly from ubiquitin-mediated proteolysis and ubiquitin ligases are the key enzymes that catalyze protein ubiquitination. We have previously shown that ubiquitin ligase Nedd4-1 is up-regulated in a rodent model of denervation- induced SM atrophy and the constitutive expression of Nedd4-1 is sufficient to induce myotube atrophy in vitro, suggesting an important role for Nedd4-1 in the regulation of muscle mass. In this study we generate a Nedd4-1 SM specific-knockout mouse and demonstrate that the loss of Nedd4-1 partially protects SM from denervation-induced atrophy confirming a regulatory role for Nedd4-1 in the maintenance of muscle mass in vivo. Nedd4-1 did not signal downstream through its known substrates Notch-1, MTMR4 or FGFR1, suggesting a novel substrate mediates Nedd4-1’s induction of SM atrophy. ii Acknowledgments and Contributions I would like to thank my supervisor, Dr. Jane Batt, for her undying support throughout my time in the laboratory.
  • Hypomorphic CARD11 Mutations Associated with Diverse Immunologic Phenotypes with Or Without Atopic Disease

    Hypomorphic CARD11 Mutations Associated with Diverse Immunologic Phenotypes with Or Without Atopic Disease

    This is a repository copy of Hypomorphic CARD11 mutations associated with diverse immunologic phenotypes with or without atopic disease.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/135712/ Version: Accepted Version Article: Dorjbal, B, Stinson, JR, Ma, CA et al. (52 more authors) (2019) Hypomorphic CARD11 mutations associated with diverse immunologic phenotypes with or without atopic disease. The Journal of Allergy and Clinical Immunology, 143 (4). pp. 1482-1495. ISSN 0091-6749 https://doi.org/10.1016/j.jaci.2018.08.013 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Reuse This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can’t change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Accepted Manuscript Hypomorphic CARD11 mutations associated with diverse immunologic phenotypes with or without atopic disease Batsukh Dorjbal, PhD, Jeffrey R. Stinson, PhD, Chi A.
  • The CARMA3-Bcl10-MALT1 Signalosome Drives NF-Κb Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer

    The CARMA3-Bcl10-MALT1 Signalosome Drives NF-Κb Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer

    Author Manuscript Published OnlineFirst on December 19, 2017; DOI: 10.1158/0008-5472.CAN-17-1089 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Molecular and Cellular Pathobiology .. The CARMA3-Bcl10-MALT1 Signalosome Drives NF-κB Activation and Promotes Aggressiveness in Angiotensin II Receptor-positive Breast Cancer. Prasanna Ekambaram1, Jia-Ying (Lloyd) Lee1, Nathaniel E. Hubel1, Dong Hu1, Saigopalakrishna Yerneni2, Phil G. Campbell2,3, Netanya Pollock1, Linda R. Klei1, Vincent J. Concel1, Phillip C. Delekta4, Arul M. Chinnaiyan4, Scott A. Tomlins4, Daniel R. Rhodes4, Nolan Priedigkeit5,6, Adrian V. Lee5,6, Steffi Oesterreich5,6, Linda M. McAllister-Lucas1,*, and Peter C. Lucas1,* 1Departments of Pathology and Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 2Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania 3McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 4Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 5Women’s Cancer Research Center, Magee-Womens Research Institute, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 6Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania Current address for P.C. Delekta: Department of Microbiology & Molecular Genetics, Michigan State University, East Lansing, Michigan Current address for D.R. Rhodes: Strata
  • The LUBAC Participates in Lysophosphatidic Acid-Induced NF-Κb Activation

    The LUBAC Participates in Lysophosphatidic Acid-Induced NF-Κb Activation

    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.13.948125; this version posted February 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The LUBAC participates in Lysophosphatidic Acid-induced NF-κB Activation Tiphaine Douanne1, Sarah Chapelier1, Robert Rottapel2, Julie Gavard1,3, Nicolas Bidère1,* 1Université de Nantes, INSERM, CNRS, CRCINA, Team SOAP, F-440000 Nantes, France; 2Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada ; 3Institut de Cancérologie de l’Ouest, Site René Gauducheau, 44800 Saint-Herblain, France *Author for correspondence: [email protected] Abstract The natural bioactive glycerophospholipid lysophosphatidic acid (LPA) binds to its cognate G protein-coupled receptors (GPCRs) on the cell surface to promote the activation of several transcription factors, including NF-κB. LPA-mediated activation of NF-κB relies on the formation of a signalosome that contains the scaffold CARMA3, the adaptor BCL10 and the paracaspase MALT1 (CBM complex). The CBM has been extensively studied in lymphocytes, where it links antigen receptors to NF-κB activation via the recruitment of the linear ubiquitin assembly complex (LUBAC), a tripartite complex of HOIP, HOIL1 and SHARPIN. Moreover, MALT1 cleaves the LUBAC subunit HOIL1 to further enhance NF- κB activation. However, the contribution of the LUBAC downstream of GPCRs has not been investigated. By using murine embryonic fibroblasts from mice deficient for HOIP, HOIL1 and SHARPIN, we report that the LUBAC is crucial for the activation of NF-κB in response to LPA. Further echoing the situation in lymphocytes, LPA unbridles the protease activity of MALT1, which cleaves HOIL1 at the Arginine 165.
  • Card9 As a Critical Regulator of Tumor Development

    Card9 As a Critical Regulator of Tumor Development

    Cancer Letters 451 (2019) 150–155 Contents lists available at ScienceDirect Cancer Letters journal homepage: www.elsevier.com/locate/canlet Mini-review Card9 as a critical regulator of tumor development T ∗ Xiaoming Zhongb,1, Bin Chenc,1, Liang Yangd, Zhiwen Yanga, a Department of Pharmacy, Songjiang Hospital Affiliated Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, China b Jiangxi Province Tumor Hospital, Nanchang, China c Surgery Department, First Affiliated Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, China d Nanjing Medical University, The Affiliated Changzhou No.2 People's Hospital, Nanjing Medical University, Nanjing, China ARTICLE INFO ABSTRACT Keywords: Caspase recruitment domain-containing protein 9 (Card9) is a myeloid cell-specific signaling protein that plays a Card9 critical role in NF-κB and MAPK activation. This leads to initiation of the inflammatory cytokine cascade, and Macrophages elicits the host immune response against microbial invasion, especially in fungal infection. Current research Tumor growth indicates that Card9 plays an important role in tumor progression. Here, we review the data from preclinical and Target therapy clinical studies of Card9 and suggest the potential for Card9-targeted interventions in the prevention or treat- ment of certain tumors. 1. Introduction humans. Among the various etiological factors, hepatitis C virus (HCV) infection is a major cause of HCC [11]. It is of great value for under- Caspase recruitment domain-containing protein 9 (Card9) is a cen- standing the HCC progression in HCV-infected patients. tral integrator of innate and adaptive immunity that is mainly expressed Zekri and colleagues studied 130 patients with HCV-associated liver in myeloid cells, especially in macrophages and dendritic cells.
  • Lymphomagenic CARD11/BCL10/MALT1 Signaling Drives Malignant B-Cell Proliferation Via Cooperative NF-Κb and JNK Activation

    Lymphomagenic CARD11/BCL10/MALT1 Signaling Drives Malignant B-Cell Proliferation Via Cooperative NF-Κb and JNK Activation

    Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation Nathalie Kniesa, Begüm Alankusa, Andre Weilemannb,c, Alexandar Tzankovd, Kristina Brunnera, Tanja Ruffa, Marcus Kremere, Ulrich B. Kellerf, Georg Lenzb,c, and Jürgen Rulanda,g,h,1 aInstitut für Klinische Chemie und Pathobiochemie, Klinikum Rechts der Isar, Technische Universität München, 81675 Munich, Germany; bTranslational Oncology, Department of Medicine A, University Hospital Münster, 48149 Münster, Germany; cCells in Motion, Cluster of Excellence EXC 1003, 48149 Münster, Germany; dInstitute of Pathology, University Hospital Basel, 4031 Basel, Switzerland; eInstitut für Pathologie, Klinikum Harlaching, 81545 Munich, Germany; fDepartment of Medicine III, Klinikum Rechts der Isar, Technische Universität München, 81675 Munich, Germany; gGerman Cancer Consortium, 69120 Heidelberg, Germany; and hGerman Center for Infection Research, 81675 München, Germany Edited by Tak W. Mak, The Campbell Family Institute for Breast Cancer Research at Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, and approved November 12, 2015 (received for review April 16, 2015) The aggressive activated B cell-like subtype of diffuse large B-cell (PI3K) (reviewed in ref. 8). The key link to the IKK complex is lymphoma is characterized by aberrant B-cell receptor (BCR) signal- the scaffolding molecule caspase recruitment domain-containing ing and constitutive nuclear factor kappa-B (NF-κB) activation, which protein 11 (CARD11), which is inactive in resting cells due to an is required for tumor cell survival. BCR-induced NF-κBactivationre- intramolecular inhibitory interaction between its linker region quires caspase recruitment domain-containing protein 11 (CARD11), and its coiled-coil domain (9).
  • PRKCQ / PKC-Theta Antibody (Aa640-690) Rabbit Polyclonal Antibody Catalog # ALS16240

    PRKCQ / PKC-Theta Antibody (Aa640-690) Rabbit Polyclonal Antibody Catalog # ALS16240

    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 PRKCQ / PKC-Theta Antibody (aa640-690) Rabbit Polyclonal Antibody Catalog # ALS16240 Specification PRKCQ / PKC-Theta Antibody (aa640-690) - Product Information Application WB, IHC Primary Accession Q04759 Reactivity Human, Mouse, Rat Host Rabbit Clonality Polyclonal Calculated MW 82kDa KDa PRKCQ / PKC-Theta Antibody (aa640-690) - Additional Information Gene ID 5588 Other Names Protein kinase C theta type, 2.7.11.13, Western blot of PKC (N670) pAb in extracts nPKC-theta, PRKCQ, PRKCT from A549 cells. Target/Specificity Human PKC Theta Reconstitution & Storage Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Precautions PRKCQ / PKC-Theta Antibody (aa640-690) is for research use only and not for use in diagnostic or therapeutic procedures. Anti-PRKCQ / PKC-Theta antibody IHC staining of human brain, cerebellum. PRKCQ / PKC-Theta Antibody (aa640-690) - Protein Information PRKCQ / PKC-Theta Antibody (aa640-690) - Name PRKCQ Background Synonyms PRKCT Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent Function serine/threonine-protein kinase that mediates Calcium-independent, phospholipid- and non- redundant functions in T-cell receptor diacylglycerol (DAG)- dependent (TCR) signaling, including T-cells activation, serine/threonine-protein kinase that proliferation, differentiation and survival, by mediates non-redundant functions in T-cell mediating activation of multiple transcription receptor (TCR) signaling, including T-cells factors such as NF-kappa-B, JUN, NFATC1 and activation, proliferation, differentiation and NFATC2. In TCR-CD3/CD28-co-stimulated Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 survival, by mediating activation of multiple T-cells, is required for the activation of transcription factors such as NF-kappa-B, NF-kappa-B and JUN, which in turn are JUN, NFATC1 and NFATC2.
  • Utilization of Genomic Sequencing for Population Screening of Immunodeficiencies in the Newborn

    Utilization of Genomic Sequencing for Population Screening of Immunodeficiencies in the Newborn

    © American College of Medical Genetics and Genomics ORIGINAL RESEARCH ARTICLE Utilization of genomic sequencing for population screening of immunodeficiencies in the newborn Ashleigh R. Pavey, MD1,2,3, Dale L. Bodian, PhD3, Thierry Vilboux, PhD3, Alina Khromykh, MD3, Natalie S. Hauser, MD3,4, Kathi Huddleston, PhD3, Elisabeth Klein, DNP3, Aaron Black, MS3, Megan S. Kane, PhD3, Ramaswamy K. Iyer, PhD3, John E. Niederhuber, MD3,5 and Benjamin D. Solomon, MD3,4,6 Purpose: Immunodeficiency screening has been added to many Results: WGS provides adequate coverage for most known state-directed newborn screening programs. The current metho- immunodeficiency-related genes. 13,476 distinct variants and dology is limited to screening for severe T-cell lymphopenia 8,502 distinct predicted protein-impacting variants were identified disorders. We evaluated the potential of genomic sequencing to in this cohort; five individuals carried potentially pathogenic augment current newborn screening for immunodeficiency, – variants requiring expert clinical correlation. One clinically including identification of non T cell disorders. asymptomatic individual was found genomically to have comple- Methods: We analyzed whole-genome sequencing (WGS) and ment component 9 deficiency. Of the symptomatic children, one clinical data from a cohort of 1,349 newborn–parent trios by was molecularly identified as having an immunodeficiency condi- genotype-first and phenotype-first approaches. For the genotype- tion and two were found to have other molecular diagnoses. first approach, we analyzed predicted protein-impacting variants in Conclusion: Neonatal genomic sequencing can potentially aug- 329 immunodeficiency-related genes in the WGS data. As a ment newborn screening for immunodeficiency. phenotype-first approach, electronic health records were used to identify children with clinical features suggestive of immunodefi- Genet Med advance online publication 15 June 2017 ciency.
  • Mtor: a Pharmacologic Target for Autophagy Regulation

    Mtor: a Pharmacologic Target for Autophagy Regulation

    mTOR: a pharmacologic target for autophagy regulation Young Chul Kim, Kun-Liang Guan J Clin Invest. 2015;125(1):25-32. https://doi.org/10.1172/JCI73939. Review mTOR, a serine/threonine kinase, is a master regulator of cellular metabolism. mTOR regulates cell growth and proliferation in response to a wide range of cues, and its signaling pathway is deregulated in many human diseases. mTOR also plays a crucial role in regulating autophagy. This Review provides an overview of the mTOR signaling pathway, the mechanisms of mTOR in autophagy regulation, and the clinical implications of mTOR inhibitors in disease treatment. Find the latest version: https://jci.me/73939/pdf The Journal of Clinical Investigation REVIEW SERIES: AUTOPHAGY Series Editor: Guido Kroemer mTOR: a pharmacologic target for autophagy regulation Young Chul Kim and Kun-Liang Guan Department of Pharmacology and Moores Cancer Center, UCSD, La Jolla, California, USA. mTOR, a serine/threonine kinase, is a master regulator of cellular metabolism. mTOR regulates cell growth and proliferation in response to a wide range of cues, and its signaling pathway is deregulated in many human diseases. mTOR also plays a crucial role in regulating autophagy. This Review provides an overview of the mTOR signaling pathway, the mechanisms of mTOR in autophagy regulation, and the clinical implications of mTOR inhibitors in disease treatment. Overview of mTOR signaling pathway such as insulin and IGF activate their cognate receptors (recep- Nutrients, growth factors, and cellular energy levels are key deter- tor tyrosine kinases [RTKs]) and subsequently activate the PI3K/ minants of cell growth and proliferation. mTOR, a serine/threon- AKT signaling axis.
  • Nuclear BCL-10 Expression Is Common in Lymphoplasmacytic Lymphoma/Waldenstro¨ M Macroglobulinemia and Does Not Correlate with P65 NF-Jb Activation

    Nuclear BCL-10 Expression Is Common in Lymphoplasmacytic Lymphoma/Waldenstro¨ M Macroglobulinemia and Does Not Correlate with P65 NF-Jb Activation

    Modern Pathology (2006) 19, 891–898 & 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenstro¨ m macroglobulinemia and does not correlate with p65 NF-jB activation Mihai Merzianu1, Liuyan Jiang2, Pei Lin1, Xuemei Wang3, Donna M Weber4, Saroj Vadhan-Raj5, Martin H Nguyen1, L Jeffrey Medeiros1 and Carlos E Bueso-Ramos1 1Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Department of Biostatistics and Applied Mathematics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4Department of Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA and 5Department of Cytokine and Supportive Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA B-cell lymphoma 10 (BCL-10) is expressed in the cytoplasm of normal germinal center and marginal zone B- cells and is involved in lymphocyte development and activation. Aberrant nuclear expression of BCL-10 occurs in a subset of extranodal marginal zone B-cell lymphomas (MALT lymphomas), primarily those with the t(1;14)(p22;q32) or t(11;18)(q21;q21). Little is known about BCL-10 expression in lymphoplasmacytic lymphoma/ Waldenstro¨ m macroglobulinemia (LPL/WM). We assessed for BCL-10 in 51 bone marrow (BM) specimens involved by LPL/WM using immunohistochemical methods. All patients had monoclonal IgM in serum. Extent of BM involvement was assessed using PAX-5/BSAP and CD20 immunostains and the pattern and percentage of B-cells positive for BCL-10 was determined.
  • SQSTM1 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis

    SQSTM1 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis

    ORIGINAL CONTRIBUTION SQSTM1 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis Faisal Fecto, MD; Jianhua Yan, MD, PhD; S. Pavan Vemula; Erdong Liu, MD; Yi Yang, MS; Wenjie Chen, MD; Jian Guo Zheng, MD; Yong Shi, MD, PhD; Nailah Siddique, RN, MSN; Hasan Arrat, MD; Sandra Donkervoort, MS; Senda Ajroud-Driss, MD; Robert L. Sufit, MD; Scott L. Heller, MD; Han-Xiang Deng, MD, PhD; Teepu Siddique, MD Background: The SQSTM1 gene encodes p62, a major In silico analysis of variants was performed to predict al- pathologic protein involved in neurodegeneration. terations in p62 structure and function. Objective: To examine whether SQSTM1 mutations con- Results: We identified 10 novel SQSTM1 mutations (9 tribute to familial and sporadic amyotrophic lateral scle- heterozygous missense and 1 deletion) in 15 patients (6 rosis (ALS). with familial ALS and 9 with sporadic ALS). Predictive in silico analysis classified 8 of 9 missense variants as Design: Case-control study. pathogenic. Setting: Academic research. Conclusions: Using candidate gene identification based on prior biological knowledge and the functional pre- Patients: A cohort of 546 patients with familial diction of rare variants, we identified several novel (n=340) or sporadic (n=206) ALS seen at a major aca- SQSTM1 mutations in patients with ALS. Our findings demic referral center were screened for SQSTM1 muta- provide evidence of a direct genetic role for p62 in ALS tions. pathogenesis and suggest that regulation of protein deg- radation pathways may represent an important thera- Main Outcome Measures: We evaluated the distri- peutic target in motor neuron degeneration. bution of missense, deletion, silent, and intronic vari- ants in SQSTM1 among our cohort of patients with ALS.
  • NF-B in Hematological Malignancies

    NF-B in Hematological Malignancies

    biomedicines Review NF-κB in Hematological Malignancies Véronique Imbert * and Jean-François Peyron Centre Méditerranéen de Médecine Moléculaire, INSERM U1065, Université Côte d’Azur, 06204 Nice, France; [email protected] * Correspondence: [email protected]; Tel.: +33-489-064-315 Academic Editor: Véronique Baud Received: 28 April 2017; Accepted: 26 May 2017; Published: 31 May 2017 Abstract: NF-κB (Nuclear Factor K-light-chain-enhancer of activated B cells) transcription factors are critical regulators of immunity, stress response, apoptosis, and differentiation. Molecular defects promoting the constitutive activation of canonical and non-canonical NF-κB signaling pathways contribute to many diseases, including cancer, diabetes, chronic inflammation, and autoimmunity. In the present review, we focus our attention on the mechanisms of NF-κB deregulation in hematological malignancies. Key positive regulators of NF-κB signaling can act as oncogenes that are often prone to chromosomal translocation, amplifications, or activating mutations. Negative regulators of NF-κB have tumor suppressor functions, and are frequently inactivated either by genomic deletions or point mutations. NF-κB activation in tumoral cells is also driven by the microenvironment or chronic signaling that does not rely on genetic alterations. Keywords: NF-κB; leukemia; lymphoma 1. Introduction The NF-κB family of transcription factors coordinates inflammatory responses, innate and adaptive immunity, cellular differentiation, proliferation, and survival in all multicellular organisms. The NF-κB system is tightly controlled at various levels, and deregulations of NF-κB homeostasis have been implicated in a wide range of diseases, ranging from inflammatory and immune disorders to cancer [1,2]. In particular, NF-κB is a key link between chronic inflammation and cancer transformation [3].